PERSPECTIVE article
Front. Pharmacol.
Sec. Drug Metabolism and Transport
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1660323
Are plasma drug concentrations still Necessary? Rethinking the pharmacokinetic link in Dose-Response relationships
Provisionally accepted- 1Faculté de Médecine, Aix Marseille Université, Marseille, France
- 2Assistance Publique - Hopitaux de Marseille, Marseille, France
- 3Aix-Marseille Universite, Marseille, France
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Plasma drug concentrations have historically played a central role in pharmacology, serving as a measurable intermediary between administered dose and clinical response. This model, linking Dose, Concentration and Effect, underpins therapeutic drug monitoring, pharmacokinetic/pharmacodynamic (PK/PD) modeling, and regulatory evaluation. Yet, numerous examples challenge the assumption that plasma concentrations are necessary or sufficient to predict drug effects. Drugs acting locally, exhibiting delayed pharmacodynamics, or relying on active metabolites often dissociate systemic levels from clinical efficacy. Furthermore, modern tools such as receptor occupancy imaging, functional biomarkers, and systems pharmacology offer richer representations of drug action. Drawing on Judea Pearl's framework for causal inference, we question whether plasma concentrations lie on the true causal pathway between dose and effect, or whether they sometimes obscure rather than reveal pharmacological mechanisms. Using clinical examples and conceptual analysis, we argue for a more selective targeted and context-sensitive use of plasma concentrations. This approach values their usefulness while cautioning against overuse. A structured decision framework is proposed to help determine when plasma monitoring is informative, and when alternative approaches may be more appropriate.
Keywords: pharmacokinetic, PK/PD (pharmacokinetics/pharmacodynamics), modeling, TDM, pharmacometric
Received: 05 Jul 2025; Accepted: 21 Jul 2025.
Copyright: © 2025 Simon and von Fabeck. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Nicolas Simon, Faculté de Médecine, Aix Marseille Université, Marseille, France
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.